Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Meloxicam
Drug ID BADD_D01374
Description Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.[A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Indications and Usage Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above.[L11398] Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. [A190189] Meloxicam, together with the local anesthetic [bupivacaine], is indicated for the production of postsurgical analgesia in adult patients for up to 72 hours following bunionectomy, open inguinal herniorrhaphy or total knee arthroplasty.[L34100]
Marketing Status approved; vet_approved
ATC Code M01AC06
DrugBank ID DB00814
KEGG ID D00969
MeSH ID D000077239
PubChem ID 54677470
TTD Drug ID D0G7FJ
NDC Product Code 72919-124; 80425-0041; 38779-2746; 53069-0790; 69237-004; 43602-623; 50090-5339; 51655-571; 55289-272; 63629-2019; 68788-1701; 70518-0171; 70518-0200; 70934-011; 70954-077; 71610-657; 71740-339; 51869-0007; 53747-006; 60592-994; 50268-526; 51655-731; 53002-2537; 60760-404; 61442-127; 63187-082; 63187-083; 70518-1630; 71610-516; 0615-8124; 72865-137; 76420-043; 49452-4402; 65862-097; 16571-776; 42708-093; 45865-360; 61442-126; 61919-434; 64380-715; 65841-050; 65841-051; 67296-1317; 67296-1460; 68071-2184; 68180-189; 68180-502; 68382-050; 68788-9418; 70518-1299; 71205-923; 71335-0406; 58118-1158; 60687-199; 60760-448; 60760-653; 67296-0823; 68788-7904; 69097-158; 70934-010; 71335-1956; 80425-0044; 51552-1377; 51869-0008; 58624-0430; 59349-0003; 70859-007; 42708-007; 51655-577; 63629-3328; 64380-716; 80425-0043; 53104-7574; 65862-098; 43063-395; 43353-979; 61919-469; 67296-1817; 68071-1919; 68180-501; 68462-140; 70518-2631; 71610-542; 0615-8040; 76282-152; 80425-0042; 80425-0083; 22365-116; 52119-003; 56125-750; 68225-112; 16571-777; 49999-869; 68382-051; 68462-141; 70518-3023; 71205-924; 71610-583; 76420-039; 17373-1157; 17373-1158; 35356-808; 43063-396; 43602-624; 51407-611; 53002-2535; 60760-419; 63629-3248; 68071-3030; 68071-4987; 68788-7726; 70954-076; 71335-1888; 71610-580; 80425-0045; 65862-223; 68981-032; 51655-177; 67296-0583; 68180-188; 71335-1618; 71610-544; 51927-0032; 43063-401; 50268-525; 67296-1250; 69097-159; 70518-1828; 71335-2080; 72865-138; 76282-153; 29300-124; 29300-125; 50090-0985; 50090-5861; 51407-610
UNII VG2QF83CGL
Synonyms Meloxicam | Miloxicam | Parocin | Mobic | Mobicox | Mobec | Masflex | Movicox | Reumoxicam | Uticox | Movalis
Chemical Information
Molecular Formula C14H13N3O4S2
CAS Registry Number 71125-38-7
SMILES CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000016%
Tremor17.01.06.002--
Unresponsive to stimuli17.02.05.0310.000024%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000032%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.000147%
Vasculitis24.12.04.027; 10.02.02.006--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.0130.000070%Not Available
Vitreous floaters06.09.01.0050.000054%
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000035%
Mental status changes19.07.01.0010.000016%Not Available
Tubulointerstitial nephritis20.05.02.0020.000067%Not Available
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.018--Not Available
Musculoskeletal disorder15.03.05.0250.000043%Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
General physical health deterioration08.01.03.018--Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000016%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000016%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.012--Not Available
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000032%
Deep vein thrombosis24.01.02.0030.000032%Not Available
Tongue eruption07.14.02.0150.000035%Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages